All News

President of NACDS, Steve Anderson, discusses how the events at Total Store Expo reflect on the association's goals of innovation and a focus on public policy.

Pharmacists are key resource points to navigate the nuances of keto diets and chronic health management.

When a community loses a pharmacy, it loses a trusted health care provider. Understanding the root causes of these closures—and what we can do about it—can drive change.

Biosimilar etanercept (Sunshine Guojian Pharmaceutical) showed similar therapeutic outcomes compared with etanercept (Enbrel; Amgen) specific to rheumatoid arthritis.

Sara Roszak recounts the Annual NACDS Foundation Dinner and their role in implementing research at the clinical level.

The use of intravenous immunoglobulin led to positive protective effects on osteoporosis.

Brandon Newman highlights the need for balanced regulation, transparency, and real-time data access to ensure fair competition and optimal outcomes for pharmacy benefit mangers.

The bispecific CAR T-cell therapy for treatment of multiple sclerosis is the first to target both CD19 and CD20.

The decision by the Supreme Court has the potential to upend the power of regulatory agencies to shape the health care landscape of the country.

These pharmacies bring high-touch specialty pharmacies into local communities for patients with more complex needs.

Joseph Saseen offers valuable insights into the implications of the added performance and quality measures for patients and health care providers.

The breakthrough therapy designation was granted based on ongoing data from the ARTEMIS-001 phase 1 open-label, multi-center trial.

SMOs offer a range of services, including site selection, patient recruitment, data management, regulatory compliance, and quality assurance.

Propofol has a history of chronic shortage due to supply chain constraints.

Jasmine Perry discusses the More Than a Script program in an interview with Pharmacy Times.

Brandon Newman discusses the significant influence of the "big 3" pharmacy benefit managers and the key legislative and regulatory efforts around transparency.

Vimseltinib (Deciphera Pharmaceuticals) has a Prescription Drug User Fee Act goal date of February 17, 2025.

The drug is currently undergoing a phase 2 clinical trial for patient 12 years or older who are hospitalized with steroid-refractory acute graft-versus-host disease (aGVHD).

The combination is the first and only multi-targeted chemotherapy-free regimen that demonstrated superiority compared with osimertinib for non–small cell lung cancer (NSCLC).

Palliative pharmacists are invaluable assets of oncologic care.

The highly potent, selective URAT1 inhibitor may help reduce serum uric acid levels and treat clinically visible tophi.

In a session at NACDS Total Store Expo, experts spoke to the success of value-based care models in the pharmaceutical industry.

Steve Anderson, president and CEO of the National Association of Chain Drug Stores (NACDS), discusses memorable moments from this year's NACDS Total Store Expo.

The study authors recommend that health care professionals are aware of the connections, notably in adolescent patients and those with moderate to severe psoriasis.

Fam-trastuzumab deruxtecan-nxki has received 4 breakthrough therapy designations, including the latest approval.